
ESOCAP ANNOUNCES THAT ITS APPLICATION DEVICE IS CE CERTIFIED AFTER MEETING THE REQUIREMENTS OF THE EUROPEAN MEDICAL DEVICE DIRECTIVE



Basel, Switzerland, February 28, 2020

EsoCap AG announced today that its application device is ready to be used in clinical studies, as it is CE certified, after meeting Swiss and EU requirements under the European Medical Device Directive. Hänggli Thermoplast AG, the producer of injection-molded plastic elements for EsoCap's application technology, has successfully fulfilled its obligations towards Swissmedic. The specially designed application device will allow optimal administration of drug substances using EsoCap's unique topical drug delivery technology.

"We are highly impressed by EsoCap's unique drug delivery platform", said Remo Hänggli, CEO Hänggli Thermoplast AG. "As a company committed to delivering expertise in plastic injection molding of pharmaceutical and medical parts, we are greatly interested in expanding our fields of application."

"We are very pleased to report this important milestone in the preparation of our clinical trial activities", said Dr. Peter Stangier, Director Strategic Planning, EsoCap. "We are confident that the EsoCap application device will benefit patients and their care teams in the treatment of a broad range of diseases of the upper gastrointestinal tract."

About EsoCap

EsoCap AG is a privately funded company based in Basel, Switzerland.

EsoCap's vision is to improve the lives of patients with serious diseases of the upper gastrointestinal tract through development of a unique topical drug delivery platform.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve, due to ultra-short transit times, with less than two seconds from mouth to stomach.

EsoCap owns a unique drug delivery platform, allowing topical application of drug substances for local treatment of diseases of the upper gastro-intestinal tract, enabling esophagus mucosa contact times never seen before.

For more information, please visit www.esocap-biotech.com.

About Thermoplast

Hänggli Thermoplast AG is a family-owned company operating since 1958. With over 50 years of experience, Hänggli Thermoplast is committed to meeting and exceeding customers' expectations in the development and production of injection-molded plastic parts and molds, with a manufacturing facility in Switzerland. The company has particularly strong expertise in the medical and pharmaceutical areas.

For more information, please visit www.thermoplast.ch



EsoCap

Contact:

Dr. Peter Stangier, Director Strategic Planning

peter.stangier@esocapbiotech.com

Isabelle Racamier, CEO

isabelle.racamier@esocapbiotech.com

EsoCap AG
Malzgasse 9
4052 Basel
Switzerland